365996-19-6Relevant articles and documents
FGFR INHIBITORS FOR THE TREATMENT OF CANCER
-
Paragraph 00195; 00199, (2020/08/28)
The disclosure provides novel FGFR inhibitors based on the pyridinylpyrimidine. The disclosure includes inhibitors with broad inhibitory activity against all FGFR isoforms, and inhibitors with selective inhibition against FGFR4. These novel pyridinylpyrimidine-based FGFR inhibitors, or their derivatives, have strong potential to be used to treat cancer.
Enzymatic dynamic kinetic resolution of (±)-cis-N-(Alkoxycarbonyl) cyclopentane-1,2-diamines based on spontaneous racemization
Quijada, F. Javier,Gotor, Vicente,Rebolledo, Francisca
supporting information; experimental part, p. 3602 - 3605 (2010/11/05)
Lipase B from Candida antarctica is an excellent catalyst for the enantioselective acetylation of different (±)-cis-N-(alkoxycarbonyl) cyclopentane-1,2-diamines. Depending on the alkoxycarbonyl group, a simple kinetic resolution (Boc-derivative) or an interesting dynamic kinetic resolution (DKR with Cbz-, Alloc, and ethoxycarbonyl derivatives) has been developed. Racemization for the DKR occurred due to the N,N′ intramolecular migration of the alkoxycarbonyl group.